• Overview
  • Eligibility
  • More info
  • Locations

High Dose Ifosfamide, Carboplatin and Etoposide With Amifostine Chemoprotection (NCT00003657)

National Cancer Institute (NCI)
The purpose of the study is to evaluate the combination of amifostine and high dose chemotherapy with blood stem cell support. Amifostine is a druf developed to protect normal tissues against the toxicities of chemotherapy and radiotherapy and has reduced the side effects of chemotherapy given at conventional doses.
  • Biological: filgrastim
    • Drug: Amifostine
      • Ethyol®
    • Drug: Carboplatin
      • Paraplatin
    • Drug: Etoposide
      • Toposar
      • VePesid
      • Etopophos
    • Drug: Ifosfamide
      • Ifex
    • Procedure: peripheral blood stem cell transplantation
      Ages eligible for Study
      18 Years to 55 Years
      Genders eligible for Study
      All
      Accepts Healthy Volunteers
      No

      3 locations

      United States (3)
      • Massachusetts General Hospital Cancer Center
        Boston, Massachusetts, United States, 02114
      • Dana-Farber Cancer Institute
        Boston, Massachusetts, United States, 02115
      • Beth Israel Deaconess Medical Center
        Boston, Massachusetts, United States, 02215
      Status:
      completed
      Type:
      Interventional
      Phase:
      Start:
      30 June, 1998
      Updated:
      18 January, 2017
      Participants:
      24
      A girl giving information about available additional trials.

      FindMeCure helps you find, understand and join clinical trials from all over the world.

      There are more clinical trials for your condition!